Month: March 2025

March 4, 2025Announcement no. 04 BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates COPENHAGEN, DENMARK, March 4, 2025 – BioPorto A/S (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announces Jens Due Olsen as a board candidate with the intention of appointing Jens Due Olsen as Chair of the Board of Directors following the Company’s Annual General Meeting on April 11, 2025. Jens Due Olsen has over 30 years of experience in leadership positions in Danish and international industrial, financial and technology companies including medico technology. Jens currently serves as chair of the Board of Directors of NKT Holding and the privately owned European Energy A/S and...

The company continues to expect to be relatively unaffected by U.S. tariffs. MONTREAL, March 04, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, provides the following comments in response to investor questions about the impact from the recently announced tariffs between the U.S. and Canada, specifically with regards to potential U.S. tariffs imposed on Canadian products. Further to our press release dated February 4, 2025, management is of the continued opinion that the imposition of tariffs will have little...

SCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, was recently honored with four Gold Award honors by the National Association of Home Builders (NAHB) at The 2024 Nationals, the home building industry’s highest awards competition. The prestigious awards are presented by the National Association of Home Builders Sales and Marketing Council to recognize the best in the building industry for their determination, integrity, creativity and endurance. The awards span categories from product and community design to advertising, marketing and sales achievements by individuals and sales teams.A panel of industry professionals selected finalists from more than 1,200 entries, and Toll Brothers’ Arizona Division was awarded as the Gold winner in the following...

Oslo, 4 March 2025: Reference is made to the exchange announcement published by Vow ASA (the “Company“) on 5 February 2025 regarding the appointment of Gunnar Pedersen as its new Chief Executive Officer, effective no later than 1 August 2025. Mr. Pedersen has today been granted synthetic options equivalent to a value of NOK 1,000,000. The options are to be cash settled, subject to a 3-year term, a strike price of NOK 4 and customary terms and conditions. This information is subject to the disclosure requirements pursuant to section 4.2.4(1) no. 1 of the Oslo Stock Exchange’s issuer rules.

NEWPORT NEWS, Va., March 04, 2025 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that shipbuilders at its Newport News Shipbuilding division have successfully installed the first valve manifold assembly created by additive manufacturing technology on a new construction aircraft carrier. NNS continues to integrate additive manufacturing, also known as 3D printing, into the shipbuilding process. The use of certified 3D-printed parts has the potential to accelerate construction and delivery of vessels to the U.S. Navy by cutting lead times and improving manufacturing quality for critical components. The valve manifold assembly, a specialized assembly that allows distribution of a single source of fluid to multiple points on the ship, is installed in a pump room on Gerald R. Ford-class aircraft carrier Enterprise (CVN 80). The...

HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. “This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “We remain focused on meeting key near term milestones and creating long-term value for our stockholders.”    The offering consists of 28,042,140 common units (or pre-funded units), each consisting of (i) one (1) share of common stock or one (1) pre-funded...

Hong Kong, March 04, 2025 (GLOBE NEWSWIRE) — Plutus Financial Group Limited (“the “Company”) (NasdaqCM: PLUT), a Hong Kong-based financial services company today announced that R.F. Lafferty & Co., Inc., who acted as lead underwriter for the Company’s underwritten initial public offering (the “IPO”), has exercised a portion of the over-allotment option and purchased an additional 150,000 ordinary shares of the Company at the IPO price of $4.00 per share. As a result, the Company has raised an additional $600,000 as result of the over-allotment, for a total of $9 million in gross proceeds, before underwriting discounts and other related expenses, through the issuance of a total of 2,250,000 ordinary shares in the IPO. R.F. Lafferty & Co., Inc. acted as lead underwriter for the IPO offering, with Revere Securities...

Trading commencing on the OTC Markets on March 5, 2025. Trading expected to continue under ticker symbol “NKGN” for common stock and “NKGNW” for warrants. NKGen Biotech, Inc. (“NKGen” or the “Company”) has regained compliance on its public reporting obligations with the filing of its most recent quarterly report on Form 10-Q on March 4, 2025; and intends to continue complying with all Securities and Exchange (“SEC”) reporting requirements. The Company has cancelled its previously announced 1-for-6 reverse stock split. Enrollment in randomized Phase 2a Alzheimer’s trial is expected to be completed by the end of Q2 with an initial readout planned for later in 2025.SANTA ANA, Calif., March 04, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company focused on the development and commercialization...